Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Industry, FDA Outline Costs Of New MDUFA Proposals; Quality Management A Strong Focus

This article was originally published in The Gray Sheet

Executive Summary

After months of negotiations, the agency has proposed hiring new staff and making significant changes to their device review process that would cost $500 million – on top of current user fee revenues – and does not account for inflation.


Related Content

FDA, Industry Agree On Working Groups To Support User-Fee Negotiations
CDRH Prioritizes Leveraging Real-World And Patient-Preference Data, Enhancing Quality
New Fundings And Goals To Match Raised In Latest MDUFA IV Session
FDA Tries To Get 'Smart' In Standardizing 510(k) Reviews